News
- Kindred Biosciences Announces Fourth Quarter and Full Year 2020 Financial ResultsMarch 16, 2021 4:02 PM EDT
- Kindred Biosciences to Announce Fourth Quarter and Full Year 2020 Financial ResultsMarch 8, 2021 8:32 AM EST
- Kindred Biosciences to Present at Barclays Global Healthcare Conference and H.C. Wainwright Global Life Sciences ConferenceMarch 2, 2021 8:31 AM EST
Events
- Tuesday, March 16, 2021 4:30 PM EDT
- Wednesday, March 10, 2021 from 2:25 PM to 2:50 PM EST
- Mar 9 - Mar 10, 2021
|
KindredBio proudly supports
Rabies Free Africa
Press Release
KindredBio intends to use the net proceeds from the offering for the development of its therapeutic candidates, the expansion of its commercial infrastructure and for other general corporate and working capital purposes.
The shares were offered pursuant to an effective shelf registration statement on Form S-3, as amended (File No. 333-222597), that was previously filed with theSecurities and Exchange Commission (SEC ) and declared effective on February 7, 2018 . A preliminary prospectus supplement and accompanying prospectus related to the offering was filed with the SEC on January 17, 2019 and is available on the SEC's website located at www.sec.gov. A final prospectus supplement and an accompanying prospectus relating to the offering was filed with the SEC on January 18, 2019 . The final prospectus supplement and accompanying prospectus may also be obtained by contacting Barclays Capital Inc. , c/o Broadridge Financial Solutions , 1155 Long Island Avenue , Edgewood, NY 11717, email: barclaysprospectus@broadridge.com, telephone: 1-888-603-5847, or Stifel, Nicolaus & Company, Incorporated , Attention: Syndicate, One Montgomery Street , Suite 3700, San Francisco, CA 94104, or by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy, nor may there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
AboutKindred Biosciences
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our expectations about the trials, regulatory approval, manufacturing, distribution and commercialization of our current and future product candidates, and statements regarding our anticipated revenues, expenses, margins, profits and use of cash.
These forward-looking statements are based on our current expectations. These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results to be materially different from any future results expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: our limited operating history and expectations of losses for the foreseeable future; the absence of significant revenue from our product candidates for the foreseeable future; our potential inability to obtain any necessary additional financing; our substantial dependence on the success of our lead product candidates, which may not be successfully commercialized even if they are approved for marketing; the effect of competition; our potential inability to obtain regulatory approval for our existing or future product candidates; our dependence on third parties to conduct some of our development activities; our dependence upon third-party manufacturers for supplies of our product candidates; uncertainties regarding the outcomes of trials regarding our product candidates; our potential failure to attract and retain senior management and key scientific personnel; uncertainty about our ability to develop a satisfactory sales organization; our significant costs of operating as a public company; our potential inability to obtain patent protection and other intellectual property protection for our product candidates; potential claims by third parties alleging our infringement of their patents and other intellectual property rights; our potential failure to comply with regulatory requirements, which are subject to change on an ongoing basis; the potential volatility of our stock price; and the significant control over our business by our principal stockholders and management.
For a further description of these risks and other risks that we face, please see the risk factors described in our filings with theSEC , including the risk factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K and any subsequent updates that may be contained in our Quarterly Reports on Form 10-Q filed with the SEC . As a result of the risks described above and in our filings with the SEC , actual results may differ materially from those indicated by the forward-looking statements made in this press release. Forward-looking statements contained in this press release speak only as of the date of this press release and we undertake no obligation to update or revise these statements, except as may be required by law.
Contact
Katja Buhrer
Katja.buhrer@kindredbio.com
(917) 969-3438
SOURCEKindred Biosciences, Inc.